Cover Image


Pulmonary Drug Delivery Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 302585
出版日期 內容資訊 英文 890 Pages
商品交期: 最快1-2個工作天內
Back to Top
肺部藥物遞輸市場機會與臨床實驗平台分析 Pulmonary Drug Delivery Market & Clinical Pipeline Insight
出版日期: 2014年05月01日 內容資訊: 英文 890 Pages



第1章 肺部藥物遞輸的簡介

第2章 肺部藥物遞輸的機制

  • 肺部藥物遞輸系統的市場區隔
  • 藥物遞輸的機制

第3章 為何需要肺部藥物遞輸

第4章 肺部藥物遞輸市場預測

  • 市場概要
  • 臨床實驗平台分析

第5章 肺部藥物遞輸市場趨勢

  • 推動市場的要素
  • 應議論課題

第6章 未來的肺部藥物遞輸市場

第7章 各相、國家、標的適應症臨床實驗趨勢

第8章 已上市藥物簡介

第9章 中斷、中止的藥物簡介

第10章 競爭環境

  • Allergan Inc.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • Boehringer Ingelheim
  • Gilead Sciences
  • Merck & Co
  • Teva Pharmaceutical
  • Novartis
  • Pfizer
  • Vectura Group



The demand for new and innovative drug delivery systems has been on a rising trend with the pharmaceutical companies concentrating on developing innovative methods for this area. It is the result of these continued efforts, which have led to the ever rising popularity of pulmonary drug delivery methods across the globe. Pulmonary drug delivery system uses the respiratory tract to deliver drugs into the lungs in order to treat diseases such as asthma, COPD and cystic fibrosis. This market has been attracting significant investments by the pharma companies with relation to development of novel treatment methods.

The system of targeted drug delivery to the lungs has become one of the most popularly investigated systemic or local drug delivery approach. With the passing of time, the drug delivery systems specifically being used for the treatment of pulmonary diseases have increased due to their potential for localized topical therapy in the lungs. One of the major advantages offered by this route is that it is possible to deposit drugs more specifically at the site with high concentrations within the diseased lung. This helps in reducing the overall amount of drug given to patients, and also increases local drug activity while simultaneously reducing systemic the side effects and first-pass metabolism.

The pulmonary technology offers an exclusive and inventive alternative for drug delivery as it allows for a systemic delivery of large and small molecule drugs through inhalation into the lungs. This mode of drug delivery have helped in reducing the adverse effects of low solubility and absorption of drugs which are present in the other therapies through the oral, intravenous and injection routes.

Owing to the rising incidences of respiratory tract related diseases like chronic obstructive pulmonary disease (COPD), asthma etc, coupled with the advancements made in the technology of drug delivery, the global market for pulmonary drug delivery system is likely to grow at a rapid rate. Additionally, the pharma companies have recently recognized the future potential of inhaled therapies and the extended application beyond asthma and COPD, and therefore, have been working towards tapping the opportunities for growth through product differentiation.

"Pulmonary Drug Delivery Market & Clinical Pipeline Analysis" Report Highlights:

  • Pulmonary Drug Delivery Market Overview
  • Favorable Market Drivers & Key Issues to be Discussed
  • Pulmonary Drug Clinical Pipeline by Phase, Disease & Country
  • Pulmonary Drug Profiles in Report: 566
  • Majority of Pulmonary Drugs in Preclinical Phase: 79
  • Number of Marketed Pulmonary Drugs: 63
  • Number of Discontinued & Suspended Drug Profiles: 283

Table of Contents

1. Introduction to Pulmonary Drug Delivery

2. Pulmonary Drug Delivery Mechanism

  • 2.1. Segments of Pulmonary Drug Delivery System
  • 2.2. Mechanisms of Drug Delivery

3. Why Need for Pulmonary Drug Delivery?

4. Pulmonary Drug Delivery Market Outlook

  • 4.1. Market Overview
  • 4.2. Clinical Pipeline Analysis

5. Pulmonary Drug Delivery Market Dynamics

  • 5.1. Favorable Market Drivers
  • 5.2. Key Issues to be Discussed

6. Future of Pulmonary Drug Delivery Market

7. Pulmonary Drug Clinical Insight by Phase, Country & Target Indication

  • 7.1. Unknown Phase
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase I
  • 7.6. Phase I/II
  • 7.7. Phase II
  • 7.8. Phase II/III
  • 7.9. Phase III
  • 7.10. Preregistration
  • 7.11. Registered

8. Marketed Pulmonary Drug Profiles

9. Suspended & Discontinued Pulmonary Drug Profiles

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Market Withdrawal
  • 9.4. Suspended

10. Competitive Landscape

  • 10.1. Allergan Inc. (MAP Pharmaceuticals)
  • 10.2. AstraZeneca (Pearl Therapeutics)
  • 10.3. Bayer HealthCare Pharmaceuticals
  • 10.4. Boehringer Ingelheim
  • 10.5. Gilead Sciences
  • 10.6. Merck & Co
  • 10.7. Teva Pharmaceutical (Microdose Therapeutx)
  • 10.8. Novartis
  • 10.9. Pfizer
  • 10.10. Vectura Group

List of Figures

  • Figure 1-1: Drug Delivery Methods
  • Figure 1-2: Evolution Timeline of Pulmonary Drug Delivery Method
  • Figure 2-1: Segments of Pulmonary Drug Delivery System
  • Figure 4-1: Global Pulmonary Drug Delivery Market (US$ Billion), 2013-2018
  • Figure 4-2: Market Segmentation of Pulmonary Drug Delivery
  • Figure 4-3: Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-4: Number of Pulmonary Drugs in Clinical Trial by Phase, 2014
  • Figure 4-5: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-6: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-7: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-8: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-9: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-10: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Back to Top